BTCY on OTC
BIOTRICITY INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Profound Medical Corp., ALLURION TECHNOLOGIES, INC. or Vivos Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Technology Fees brought in 90% of the revenue BIOTRICITY INC. broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2025 | 2026 |
|---|---|---|
| Technology Fees | $12.6M | $14.4M |
| Device Sales | $1.2M | $1.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue19¢$3.0M
- Research and development17¢$2.8M
- Selling, general and admin53¢$8.5M
- Other costs11¢$1.7M
Out of $16.0M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| REVENUE | $16.0M | $13.8M |
| Cost of Revenue | $3.0M | $3.2M |
| GROSS PROFIT | $12.9M | $10.6M |
| Selling, general and administrative expenses | $8.5M | $10.9M |
| Research and development expenses | $2.8M | $2.2M |
| TOTAL OPERATING EXPENSES | $11.3M | $13.0M |
| INCOME (LOSS) FROM OPERATIONS | $1.7M | -$2.4M |
| Other income/(expense) [Note 3] | $160.0K | -$78.6K |
| Interest expense | -$3.4M | -$3.3M |
| Gain/(Loss) upon convertible promissory notes conversion and redemption [Note 8] | $19.8K | -$137.9K |
| Accretion and amortization expenses | -$745.9K | -$1.9M |
| Change in fair value of derivative liabilities [Note 8] | -$167.3K | -$553.9K |
| NET LOSS BEFORE INCOME TAXES | -$2.4M | -$8.4M |
| NET LOSS BEFORE DIVIDENDS | -$2.4M | -$8.4M |
| Preferred Stock Dividends | -$724.3K | -$466.1K |
| Deemed Dividend | -$3.1M | |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | -$3.1M | -$11.9M |
| Translation adjustment | -$35.5K | $113.4K |
| COMPREHENSIVE LOSS | -$3.2M | -$11.8M |
| LOSS PER SHARE, BASIC | -$0.12 | -$0.56 |
| LOSS PER SHARE, DILUTED | -$0.12 | -$0.56 |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC | 27.3M shares | 21.5M shares |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED | 27.3M shares | 21.5M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash | $149.8K | $365.1K | |
| Accounts receivable, net [Note 3] | $2.9M | $1.7M | |
| Inventory [Note 3] | $1.3M | $1.6M | |
| Deposits and other receivables | $1.4M | $1.1M | |
| Total current assets | $5.9M | $4.6M | |
| Deposits and other receivables [Note 12] | $109.3K | $109.3K | |
| Long-term accounts receivable | $130.8K | $70.7K | |
| Property and equipment [Note 13] | $3.6K | $9.6K | |
| Operating right of use assets [Note 12] | $346.2K | $812.1K | $1.2M |
| TOTAL ASSETS | $6.4M | $5.6M | |
| Accounts payable and accrued liabilities [Note 4] | $9.0M | $7.7M | |
| Convertible promissory notes and short term loans [Note 5] | $11.1M | $9.6M | |
| Term loans, current [Note 6] | $14.7M | $2.4M | |
| Derivative liabilities [Note 8] | $445.9K | $424.2K | |
| Advance from customers | $1.5M | ||
| Operating lease obligations, current [Note 12] | $397.8K | $531.3K | |
| Total current liabilities | $37.1M | $20.6M | |
| Federally guaranteed loans [Note 7] | $870.8K | $870.8K | |
| Term loans [Note 6] | $12.3M | ||
| Derivative liabilities [Note 8] | $1.4M | $1.5M | $1.4M |
| Operating lease obligations | $397.8K | ||
| TOTAL LIABILITIES | $39.4M | $35.7M | |
| Series B Convertible Redeemable preferred stock, $0.001 par value, 600 shares authorized as of March 31, 2026 and March 31, 2025, respectively, 335 and 385 shares issued and outstanding as of March 31, 2026 and March 31, 2025, respectively [Note 9] | $1.7M | $2.0M | |
| Preferred stock, value | $1 | $1 | |
| Common stock, $0.001 par value, 125,000,000 authorized as at March 31, 2026 and March 31, 2025. Issued and outstanding common shares: 28,597,315 and 26,081,295 as at March 31, 2026 and March 31, 2025, respectively, and exchangeable shares of 160,672 outstanding as at March 31, 2026 and March 31, 2025. [Note 9] | $28.8K | $26.2K | |
| Shares to be issued 1,005,815 and 324,276 shares of common stock as at March 31, 2026 and March 31, 2025, respectively [Note 9] | $284.7K | $284.2K | |
| Additional paid-in-capital | $107.6M | $107.1M | |
| Accumulated other comprehensive loss | -$41.9K | -$6.4K | |
| Accumulated deficit | -$142.6M | -$139.4M | |
| Total stockholders equity (deficiency) | -$34.7M | -$32.0M | -$31.5M |
| TOTAL LIABILITIES, MEZZANINE AND STOCKHOLDERS DEFICIENCY | $6.4M | $5.6M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 1 shares | 1 shares | |
| Preferred stock, shares outstanding | 1 shares | 1 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 125.0M shares | 125.0M shares | |
| Common stock, shares, issued | 28.6M shares | 26.1M shares | |
| Common stock, shares, outstanding | 28.6M shares | 26.1M shares | |
| Common stock, other shares, outstanding | 160.7K shares | 160.7K shares | |
| Common stock shares to be issued | 1.0M shares | 324.3K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Net loss before dividends | -$2.4M | -$8.4M |
| Stock based compensation | $25.6K | $1.5M |
| Issuance of shares for services | $3.8K | $320.9K |
| Issuance of warrants for brokers, at fair value | $38.1K | |
| Accretion and amortization expenses | $745.9K | $1.9M |
| Change in fair value of derivative liabilities | $167.3K | $553.9K |
| (Gain) Loss on debt conversion and redemption | -$1.3K | $137.9K |
| Loss upon settlement of accounts payable | $249.1K | |
| Property and equipment depreciation | $6.0K | $6.0K |
| Accounts receivable, net | -$1.3M | -$110.9K |
| Operating right of use assets amortization | $465.8K | $409.5K |
| Inventory | $214.1K | $324.0K |
| Deposits and other receivables | -$372.5K | -$747.8K |
| Advance from Customers | $1.5M | |
| Accounts payable and accrued liabilities and lease obligations | $195.1K | $1.5M |
| Net cash used in operating activities | -$719.0K | -$2.4M |
| Issuance of common shares, net | $125.2K | |
| Issuance of preferred shares, net | $1.7M | |
| Redemption of preferred shares | -$200.0K | |
| Proceeds from convertible debentures, net | $1.8M | |
| Proceeds from (repayment of) short term loan and promissory notes, net | $1.4M | -$1.7M |
| Term Loan, net | -$600.0K | |
| Preferred Stock Dividend | -$24.0K | -$30.0K |
| Net cash provided by financing activities | $557.7K | $1.9M |
| Effect of foreign currency translation | -$54.1K | $30.0K |
| Net increase (decrease) in cash during the year | -$161.2K | -$450.9K |
| Interest paid | $2.9M | $3.6M |
| Conversion of Series B notes into common stock | $434.0K | $6.0M |
| Conversion of convertible notes into common stock | $2.4M | |
| Warrants issued and recorded as debt discount | $38.1K |
Former names
- METASOLUTIONS, INC.Jan 27, 2015 to Jan 5, 20163
Recent filings
- Oct 7, 2026RW
- Sep 28, 20268-K
- Aug 19, 202610-Q
- Aug 17, 2026NT 10-Q
- Aug 14, 2026SCHEDULE 13G/A
- Jul 14, 202610-K
- Jun 29, 2026NT 10-K
- Jun 16, 2026DEF 14C
- May 29, 2026PRE 14C
- May 12, 2026SCHEDULE 13G/A
- May 1, 20268-K
- Feb 18, 20268-K
- Feb 11, 202610-Q
- Feb 4, 2026SCHEDULE 13G/A
- Dec 19, 2025S-1
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBIOTRICITY INC. filings on SEC EDGAR
- 2SEC EDGARBIOTRICITY INC. 10-K for fiscal 2026
- 3SEC EDGARBIOTRICITY INC. filings on SEC EDGAR
- 4SEC EDGARBIOTRICITY INC. 10-K for fiscal 2019
- 5SEC EDGARBIOTRICITY INC. 10-K for fiscal 2020
- 6SEC EDGARBIOTRICITY INC. 10-K for fiscal 2021
- 7SEC EDGARBIOTRICITY INC. 10-K for fiscal 2022
- 8SEC EDGARBIOTRICITY INC. 10-K for fiscal 2023
- 9SEC EDGARBIOTRICITY INC. 10-K for fiscal 2024
- 10SEC EDGARBIOTRICITY INC. 10-Q for fiscal 2025
- 11SEC EDGARBIOTRICITY INC. 10-Q for fiscal 2025
- 12SEC EDGARBIOTRICITY INC. 10-Q for fiscal 2026